Digital Disruption

The clinical research industry is making strides in technological innovation, with small but steady increases to the percentage of companies implementing and piloting digital technologies. However, our 2024 digital disruption survey conducted with Citeline shows a slower pace of innovation than predicted by the 2019 survey. Why is this the case?

The necessary caution in the industry, paired with biopharma’s focus on maintaining beneficial returns on investment within a complex, high-cost, high-risk environment, creates unique changes as optimism around innovation meets the challenges of implementation.

• The evolving value perceptions, barriers and attitudes toward digital innovation informed by our 2024 digital disruption survey 
• Current technology trends, the impact on investment across the industry and within pharmaceutical organisations
• Disruptions within the CRO realm and the shifts in outsourcing, services and digital solutions provision
• Considerations for an integrated approach to digital tools and artificial intelligence to optimise the benefits of their adoption

Download the whitepaper to explore the data from our survey and learn how pharmaceutical organisations can get clarity on the risks and benefits of implementing intelligent solutions.